By Fineline Cube 
Nuance Pharma, an innovation-focused biopharmaceutical company, and Stallergenes Greer, a global leader in the allergy sector, announced today that they have entered into an exclusive long-term partnership agreement. The collaboration centers on the development and commercialization of Actair, Stallergenes Greer’s sublingual allergen immunotherapy (SLIT) tablet for treating house dust mite (HDM)-induced allergic rhinitis.
Partnership Details
Under the agreement, Stallergenes Greer and Nuance Pharma will collaborate on the development and registration of Actair in China. Nuance Pharma will handle the commercialization of Actair in the Chinese market.
Market Opportunity
Chinese guidelines recommend respiratory allergen immunotherapy (AIT) as a first-line treatment for allergic rhinitis, especially in moderate to severe cases. However, uptake remains limited. Actair’s introduction aims to address this gap by offering a convenient treatment option for patients with HDM-induced allergies.
Global Presence
Stallergenes Greer’s SLIT tablet for HDM-induced allergic rhinitis is already commercialized in 21 countries and territories under the brand names Actair, Orylmyte, or Aitmyte, with plans to expand further.-Fineline Info & Tech